Pay in 4 interest-free payments of $5.20 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
The key findings from this clinical program include significant reductions in body weight and fat mass in treatment groups compared to placebo, preferential loss of abdominal and visceral adipose tissue, no changes in serum IGF-1 levels at any dose tested, no negative effects on glucose metabolism or insulin sensitivity, no significant adverse events related to metabolic or endocrine disruption, and safety profile indistinguishable from placebo for most parameters
For solution trials, prepare fresh aliquots and follow institutional stability protocols
Reconstitution requires 3 mL of bacteriostatic water drawn slowly into the vial, swirled gently, never shaken
Book your free vitamin injections consultation
Also known as Bepecin, BPC 157, Body Protection Compound 157, Pentadecapeptide BPC-157, PCO-02 Evidence records Studies, registries, reviews, and regulatory records Registered human trials NCT02637284 is a Phase 1 oral safety and pharmacokinetics study in healthy volunteers
US$ 23.46
US$ 23.63
US$ 27.77
US$ 29.80
